Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2024 Apr 27;15:3599. doi: 10.1038/s41467-024-48010-z

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2024

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 5 — a Architecture of untreated MDA-MB-435s-based VTSs. 3D-rendering of CD31⁺-PV surfaces (red) with TCs (green orbs), and fibroblasts (blue orbs). Frontal cut through VTS center in the xy-plane. a’ 3D-rendering of CD31⁺-PV surfaces in the same view, colored to represent the different structural objects. b Architecture of MDA-MB-435s-based VTSs after treatment with AXI. 3D-rendering of CD31⁺-PV surfaces (red) with TCs (green orbs), and fibroblasts (blue orbs). Frontal cut through VTS center in the xy-plane. b’ 3D-rendering of CD31⁺-PV surfaces in the same view, colored to represent the different structural objects. c Tracing of PV networks in MDA-MB-435s-based VTSs treated with three different anti-angiogenic agents. 3D-rendering of surfaces and segments colored according to diameter. d Absolute volumes of CD31⁺-cells within MDA-MB-435s-based VTSs after treatment. e Absolute volumes of CD31⁺-cells within MDA-MB-231-based VTSs after treatment. f Volumes of individual CD31⁺-PV networks identified by tracing in MDA-MB-435s-based VTSs after treatment. g Volumes of individual CD31⁺-PV networks identified by tracing in MDA-MB-231-based VTSs after treatment. h Distribution of PV-segment diameters in MDA-MB-435s-based VTSs after treatment. N = 3, error bars: not shown for clarity. i Distribution of PV-segment diameters in MDA-MB-231-based VTSs after treatment. Error bars: not shown for clarity. j Comparison of distances of TCs and fibroblasts in MDA-MB-435s-based VTSs from nearest PV after treatment. k Comparison of distances of TCs and fibroblasts in MDA-MB-231-based VTSs from nearest PV after treatment. 3D grid spacing: 50 µm, error bars: ± SEM, analyzed with unpaired two-tailed t-test against CTRL, n = 3 (except MDA-MB-231 DesOH LY-411575: n = 4) individual biological samples. Source data are provided as a Source Data file.